Detalhe da pesquisa
1.
Combination therapy with anti-HIV-1 antibodies maintains viral suppression.
Nature
; 561(7724): 479-484, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30258136
2.
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.
Nature
; 535(7613): 556-60, 2016 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27338952
3.
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
Nature
; 522(7557): 487-91, 2015 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-25855300
4.
Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
Nature
; 535(7613): 580, 2016 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27007847
5.
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.
PLoS One
; 14(8): e0219142, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31393868
6.
Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117.
J Exp Med
; 215(9): 2311-2324, 2018 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30072495
7.
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.
Nat Med
; 24(11): 1701-1707, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30258217
8.
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.
Nat Med
; 23(2): 185-191, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28092665